USFDA issues Form 483 with 8 observations to Aurobindo's Telangana unit

Aurobindo Pharma faces scrutiny. The US FDA inspected its Bachupally, Telangana plant. The inspection occurred between August 25 and September 5. Following the inspection, the US FDA issued a Form 483. The form contained eight observations. Aurobindo Pharma stated the observations are procedural. The company plans to respond to the US FDA within the given timeframe.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kXtOaJq
via IFTTT